

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest in Intellectual Property
CONVEYING PARTY DATA	
Name	Execution Date
GENERAL ELECTRIC CAPITAL CORPORATION	09/07/2010
RECEIVING PARTY DATA	
Name:	BIONICHE PHARMA GROUP LIMITED
Street Address:	272 E. DEERPATH ROAD
Internal Address:	SUITE 304
City:	LAKE FOREST
State/Country:	ILLINOIS
Postal Code:	60045
Name:	BIONICHE TEORANTA
Street Address:	272 E. DEERPATH ROAD
Internal Address:	SUITE 304
City:	LAKE FOREST
State/Country:	ILLINOIS
Postal Code:	60045
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	5880108
Patent Number:	5888986
Patent Number:	5591724
Patent Number:	6667296
Patent Number:	5019583
Patent Number:	5466700
Patent Number:	5866591
Patent Number:	5599938

501288171

PATENT
REEL: 024973 FRAME: 0258

OP \$400.00 5880108

Patent Number:	7220858
Application Number:	10745232
CORRESPONDENCE DATA	
Fax Number:	(866)826-5420
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	3016380511
Email:	ipresearchplus@comcast.net
Correspondent Name:	IP Research Plus, Inc.
Address Line 1:	21 Tadcaster Circle
Address Line 2:	Attn: Penelope J.A. Agodoa
Address Line 4:	Waldorf, MARYLAND 20602
ATTORNEY DOCKET NUMBER:	36093
NAME OF SUBMITTER:	Penelope J.A. Agodoa
Total Attachments: 10 source=36093#page1.tif source=36093#page2.tif source=36093#page3.tif source=36093#page4.tif source=36093#page5.tif source=36093#page6.tif source=36093#page7.tif source=36093#page8.tif source=36093#page9.tif source=36093#page10.tif	

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (the "Release") is made as of the 7th day of September 2010, between **BIONICHE PHARMA GROUP LIMITED**, a company incorporated under the laws of Ireland with number 313327, **BIONICHE TEORANTA**, a company incorporated under the laws of Ireland with number 130418 (the "Assignees") and **GENERAL ELECTRIC CAPITAL CORPORATION**, individually and in its capacity as agent under the Agreements described below (the "Assignor").

WHEREAS, in connection with certain loan documents, Assignees and Assignor entered into certain loan and security agreements (as amended, supplemented, or otherwise modified from time to time, the "Agreements") for the purpose of securing certain obligations of Assignees to Assignor;

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of November 12, 2009, which was recorded in the United States Patent and Trademark Office on November 17, 2009, at Reel/Frame 023525/0222, and that certain Amended and Restated Intellectual Property Security Agreement, dated as of December 16, 2008, which was recorded in the United States Patent and Trademark Office on December 16, 2008, at Reel/Frame 021985/0247 with respect to patents and at Reel/Frame 3904/0923 with respect to trademarks (collectively, the "IP Security Agreements"), Assignees granted, assigned, conveyed, mortgaged, pledged, hypothecated, and transferred to the Assignor a continuing first priority security interest in and Lien upon all of its right, title and interest in, to and under certain intellectual property (as defined in the Agreements), including but not limited to the Intellectual Property Collateral as defined in the IP Security Agreements, and including but not limited to the Patents identified on Exhibits A and B attached hereto, the Trademarks identified on Exhibit C attached hereto and the Copyrights identified on Exhibit D attached hereto (collectively, the "Released Intellectual Property"), and pledged and mortgaged (but did not transfer title to) the Released Intellectual Property Collateral to Assignor; and

WHEREAS, all of the indebtedness and other obligations secured by Assignor's security interest in the Released Intellectual Property Collateral have been repaid in their entirety, and Assignor is therefore obligated to release its security interest in the Released Intellectual Property Collateral.

NOW, THEREFORE, for valuable consideration and pursuant to the terms and conditions set forth in the Agreements and the IP Security Agreements:

Assignor hereby terminates and releases its security interest in the Released Intellectual Property Collateral, including without limitation, the Patents identified on Exhibits A and B attached hereto, the Trademarks identified on Exhibit C attached hereto and the Copyrights identified on Exhibit D attached hereto, and Assignor hereby assigns and transfers to Assignees the Assignor's entire right, title, and interest in and to the Released Intellectual Property Collateral, effective as of the date set forth above.

Assignor hereby agrees to execute such further instruments and documents and perform such further acts as Assignees may deem necessary to secure to Assignees the rights herein conveyed.

"ASSIGNOR"

GENERAL ELECTRIC CAPITAL CORPORATION

By: 


Name: KEVIN RITZ

Title: Duly Authorized Signatory


RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
SIGNATURE PAGE

"ASSIGNEES"

For and on behalf of
BIONICHE PHARMA GROUP LIMITED

By: 
Name: STEVEN THORNTON
Title: Director

For and on behalf of
BIONICHE TEORANTA

By: 
Name: STEVEN THORNTON
Title: Director

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
SIGNATURE PAGE

PATENT

REEL: 024973 FRAME: 0263

EXHIBIT A

PATENT REGISTRATIONS:

Method for treating the internal urinary bladder and associated structures using hyaluronic acid	U.S.	5,880,108 3/9/1999	Bioniche Teoranta
Method for treating the urinary bladder and associated structures using hyaluronic acid	U.S.	5,888,986 3/30/1999	Bioniche Teoranta
Method for treating the urinary bladder and associated structures using hyaluronic acid	U.S.	5,591,724 1/7/1997	Bioniche Teoranta
Method for preventing, reducing, and treating radiation cystitis using hyaluronic acid	U.S.	6,667,296 12/23/2003	Bioniche Teoranta
N-PHENYL-N-(4-PIPERIDINYL)AMIDES USEFUL AS ANALGESICS	U.S.	5,019,583 5/28/91	Bioniche Teoranta
ANESTHETIC USE OF N-PHENYL-N-(4-PIPERIDINYL)AMIDES	U.S.	5,466,700 11/14/95	Bioniche Teoranta
STABLE FORMULATIONS OF REMIFENTANIL	U.S.	5,866,591 2/2/99	Bioniche Teoranta
PROCESS FOR PREPARING A PIPERIDINE DERIVATIVE	U.S.	5,599,938 2/4/97	Bioniche Teoranta

PATENT APPLICATIONS:

Reference is made to Section I above (patent Registrations).

EXHIBIT B

PATENT REGISTRATIONS:

Title	Country	Patent Number	Issue Date	Owner
Synthesis of Hydrazine Derivatives of Pyridazine	United States of America	7,220,858	May 22, 2007	Bioniche Teoranta

PATENT APPLICATIONS:

Title	Country	Application Number	Filing Date	Owner
Stable Hydralazine Pharmaceutical Formulations	United States of America	10/745,232	December 23, 2003	Bioniche Teoranta

EXHIBIT C

N/A

EXHIBIT D

N/A